argenex SE $ARGX Shares Newly Purchased by Guardian Partners Inc.

Guardian Partners Inc. purchased a new position in shares of argenex SE (NASDAQ:ARGX) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 900 shares of the company’s stock, valued at approximately $863,000.

Several other institutional investors also recently added to or reduced their stakes in ARGX. WPG Advisers LLC increased its position in argenex by 17.8% during the first quarter. WPG Advisers LLC now owns 86 shares of the company’s stock worth $63,000 after buying an additional 13 shares during the period. Mather Group LLC. lifted its stake in argenex by 19.1% in the third quarter. Mather Group LLC. now owns 81 shares of the company’s stock valued at $78,000 after buying an additional 13 shares during the last quarter. Farther Finance Advisors LLC boosted its holdings in shares of argenex by 3.6% in the third quarter. Farther Finance Advisors LLC now owns 378 shares of the company’s stock valued at $363,000 after acquiring an additional 13 shares during the period. NewEdge Advisors LLC boosted its holdings in shares of argenex by 2.8% in the first quarter. NewEdge Advisors LLC now owns 523 shares of the company’s stock valued at $382,000 after acquiring an additional 14 shares during the period. Finally, Nvwm LLC boosted its holdings in shares of argenex by 1.3% in the third quarter. Nvwm LLC now owns 1,538 shares of the company’s stock valued at $1,475,000 after acquiring an additional 20 shares during the period. Institutional investors and hedge funds own 60.32% of the company’s stock.

argenex Stock Performance

NASDAQ:ARGX opened at $890.05 on Thursday. argenex SE has a 1 year low of $661.85 and a 1 year high of $1,072.75. The stock has a fifty day moving average price of $955.80 and a two-hundred day moving average price of $884.54. The stock has a market capitalization of $55.98 billion, a price-to-earnings ratio of 34.18, a PEG ratio of 0.80 and a beta of 0.44.

argenex (NASDAQ:ARGX) last issued its earnings results on Tuesday, July 21st. The company reported $7.32 EPS for the quarter, topping the consensus estimate of $5.86 by $1.46. The company had revenue of $1.54 billion for the quarter, compared to analyst estimates of $1.45 billion. argenex had a net margin of 32.19% and a return on equity of 43.59%. On average, analysts predict that argenex SE will post 28.71 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on ARGX. Barclays restated a “buy” rating on shares of argenex in a research report on Monday, September 7th. Citizens Jmp increased their price target on shares of argenex from $932.00 to $1,200.00 and gave the stock a “market outperform” rating in a research note on Tuesday, August 18th. UBS Group upgraded shares of argenex from a “neutral” rating to a “buy” rating and increased their price target for the stock from $960.00 to $1,400.00 in a research note on Wednesday, August 26th. Citigroup raised their price objective on shares of argenex from $1,152.00 to $1,182.00 and gave the stock a “buy” rating in a research report on Tuesday, July 21st. Finally, Wall Street Zen upgraded shares of argenex from a “hold” rating to a “buy” rating in a research note on Saturday, October 17th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $1,148.00.

About argenex

argenx SE (NASDAQ: ARGX) is a global immunology company focused on developing and commercializing therapies for patients with severe autoimmune diseases. The company uses its antibody engineering capabilities to discover and advance medicines designed to target disease-causing immune mechanisms.

argenx’s lead product is VYVGART (efgartigimod alfa), an antibody fragment that targets the neonatal Fc receptor, or FcRn, to reduce levels of disease-causing immunoglobulin G antibodies. VYVGART is approved in several markets for the treatment of generalized myasthenia gravis.